Actively Recruiting
Evaluation of RN1201 Allogeneic CAR-T Cell Therapy as Initial Treatment for Adults with Newly Diagnosed Multiple Myeloma
Led by The First Affiliated Hospital of Soochow University · Updated on 2026-06-16
18
Participants Needed
1
Research Sites
47 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating RN1201, an allogeneic CAR-T cell therapy targeting BCMA and CD19, as a first-line treatment for adults newly diagnosed with multiple myeloma. This phase 1, single-arm, dose-escalation study aims to assess the safety and effectiveness of RN1201 in this patient population. The study focuses on treatment-emergent adverse events and response rates, including minimal residual disease status. Participants will receive lymphodepletion chemotherapy followed by a single infusion of RN1201. The treatment period includes monitoring for dose-limiting toxicities within 28 days after infusion and ongoing assessment of safety up to 24 months post-treatment. The study also evaluates pharmacokinetics and pharmacodynamics of RN1201 for up to 52 weeks, with secondary outcomes measured at multiple intervals up to one year. Throughout the study, participants will undergo regular evaluations to monitor safety and treatment response. These include clinical assessments, laboratory tests, and monitoring for adverse events. Effectiveness will be assessed at 4 weeks, 3 months, 6 months, and 12 months after treatment. The total participation duration may extend up to two years to ensure comprehensive safety and efficacy data are collected.
CONDITIONS
Brief Title
Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
Research Team
X
Xiaowen Tang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here